Trial reportLeukemia2016
Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS).
Abstract readClinical TrialLetterMulticenter Study
In one paragraph
Trial report in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide.Genes, chromosomes & cancer · 2025Trial
- Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q).Annals of hematology · 2021Trial
- Trial
- Venetoclax combined with azacitidine in the treatment of secondary myelodysplastic syndrome following multiple myeloma: a case report and literature review.Frontiers in oncology · 2026Article
- Clinical and Biological Insights into Myelodysplastic Neoplasms Associated with Deletions of Chromosome 5q Region.Hematology reports · 2025Review
- Non-curative therapies and their impact on the prognosis of patients with myelodysplastic syndromes- a retrospective matched-pairs analysis.Annals of hematology · 2025Article
- Two ways to complex karyotype in MDS-the role of del(5q) and TP53.Blood cancer journal · 2025Article
- Expression levels of genes implicated in the working mechanism of lenalidomide predict treatment response in lower risk myelodysplastic syndrome patients.Haematologica · 2025Article
- From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy.Biomarker research · 2024Review
- Article
- Treatment-emergent mutations in myelodysplastic syndrome with del(5q) - lenalidomide related or disease-intrinsic clonal evolution?Blood cancer journal · 2024Article
- Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes.Blood advances · 2023Article
- Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.American journal of hematology · 2023Review
- Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS).Current oncology (Toronto, Ont.) · 2023Review
- Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes.Current treatment options in oncology · 2023Review
- The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia.International journal of molecular sciences · 2023Review
- How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms.Clinical hematology international · 2023Review
- Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide.Blood cancer journal · 2022Article
- Past, present and future in low-risk myelodysplastic syndrome.Frontiers in medicine · 2022Review
- Allogeneic haematopoietic stem cell transplantation with decitabine-containing preconditioning regimen in TP53-mutant myelodysplastic syndromes: A case study.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
M MossnerIII. Medizinische Klinik, Hämatologie und Onkologie, Universitätsmedizin Mannheim, Mannheim, Germany.
J-C JannIII. Medizinische Klinik, Hämatologie und Onkologie, Universitätsmedizin Mannheim, Mannheim, Germany.
D NowakIII. Medizinische Klinik, Hämatologie und Onkologie, Universitätsmedizin Mannheim, Mannheim, Germany.
U PlatzbeckerMedizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Dresden, Germany.
A GiagounidisKlinik für Hämatologie, Onkologie und Palliativmedizin, Marienhospital, Düsseldorf, Germany.
K GötzeIII. Medizinischen Klinik des Klinikums rechts der Isar der Technischen Universität München, München, Germany.
A LetschMedizinische Klinik für Hämatologie, Onkologie, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Berlin, Germany.
D HaaseAbteilung für Hämatologie und Onkologie, Universitätsmedizin Göttingen, Göttingen, Germany.
K ShirneshanAbteilung für Hämatologie und Onkologie, Universitätsmedizin Göttingen, Göttingen, Germany.
F BraulkeAbteilung für Hämatologie und Onkologie, Universitätsmedizin Göttingen, Göttingen, Germany.
R F SchlenkKlinik für Innere Medizin III, Zentrum für Innere Medizin, Universitätsklinikum Ulm, Ulm, Germany.
T HaferlachMLL Münchner Leukämielabor GmbH, München, Germany.
P SchafhausenII. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
G BugMedizinische Klinik II, Abteilung für Hämatologie/Onkologie, Klinikum der J.W. Goethe-Universität Frankfurt, Frankfurt, Germany.
M LübbertAbteilung für Innere Medizin I, Hämatologie und Onkologie, Universitätsklinikum Freiburg, Freiburg, Germany.
A GanserAbteilung für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Medizinische Hochschule Hannover, Hannover, Germany.
G BüscheInstitut für Pathologie, Zentrum für Pathologie, Forensik und Genetik, Medizinische Hochschule Hannover, Hannover, Germany.
E SchulerAbteilung für Hämatologie, Onkologie und klinische Immunologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany.
V NowakIII. Medizinische Klinik, Hämatologie und Onkologie, Universitätsmedizin Mannheim, Mannheim, Germany.
J PresslerIII. Medizinische Klinik, Hämatologie und Onkologie, Universitätsmedizin Mannheim, Mannheim, Germany.
J ObländerIII. Medizinische Klinik, Hämatologie und Onkologie, Universitätsmedizin Mannheim, Mannheim, Germany.
S FeyIII. Medizinische Klinik, Hämatologie und Onkologie, Universitätsmedizin Mannheim, Mannheim, Germany.
N MüllerIII. Medizinische Klinik, Hämatologie und Onkologie, Universitätsmedizin Mannheim, Mannheim, Germany.
E Lauinger-LörschIII. Medizinische Klinik, Hämatologie und Onkologie, Universitätsmedizin Mannheim, Mannheim, Germany.
G MetzgerothIII. Medizinische Klinik, Hämatologie und Onkologie, Universitätsmedizin Mannheim, Mannheim, Germany.
C WeißAbteilung für Medizinische Statistik, Biomathematik und Informationsverarbeitung, Medizinische Fakultät Mannheim der Universität Heidelberg, Heidelberg, Germany.
W-K HofmannIII. Medizinische Klinik, Hämatologie und Onkologie, Universitätsmedizin Mannheim, Mannheim, Germany.
U GermingAbteilung für Hämatologie, Onkologie und klinische Immunologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany.
F NolteIII. Medizinische Klinik, Hämatologie und Onkologie, Universitätsmedizin Mannheim, Mannheim, Germany.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
MutationAdultAgedAged, 80 and overChromosome DeletionChromosomes, Human, Pair 5FemaleHumansImmunologic FactorsLenalidomideMaleMiddle AgedMyelodysplastic SyndromesPrevalenceProspective StudiesThalidomideImmunologic FactorsLenalidomideThalidomideTP53 protein, humanTumor Suppressor Protein p53
Identifiers
PMID
27133825What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.